INNV:OTCQB-Innovus Pharms Inc (USD)

COMMON STOCK | Medical Care Facilities | OTCQB - U.S. Registered

Last Closing

USD 4.5

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.02M

Analyst Target

USD 5.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Innovus Pharmaceuticals Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of prescription and non-prescription medicine and consumer care products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-25 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
ENSG The Ensign Group Inc

N/A

USD 6.78B
ACHC Acadia Healthcare Company Inc

N/A

USD 6.07B
OPCH Option Care Health Inc

N/A

USD 5.07B
SGRY Surgery Partners Inc

N/A

USD 3.24B
AMED Amedisys Inc

N/A

USD 3.00B
LFST Lifestance Health Group Inc

N/A

USD 2.16B
ADUS Addus HomeCare Corporation

N/A

USD 1.91B
ASTH Astrana Health Inc

N/A

USD 1.79B
HCSG Healthcare Services Group Inc

N/A

USD 0.77B
PNTG Pennant Group Inc

N/A

USD 0.68B

ETFs Containing INNV

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.00% 50% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.00% 50% F 22% F
Trailing 12 Months  
Capital Gain -25.50% 46% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.50% 46% F 29% F
Trailing 5 Years  
Capital Gain 116.35% 80% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.35% 80% B- 84% B
Average Annual (5 Year Horizon)  
Capital Gain 223.22% 100% F 97% N/A
Dividend Return 223.22% 100% F 97% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 505.81% 7% C- 4% F
Risk Adjusted Return 44.13% 79% B- 76% C+
Market Capitalization 0.02B 62% D 66% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector